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1. Introduction 
Over the past decade, accumulating evidence has implicated the phenomenon of epigenetic 
dysregulation in a variety of cancers (Biermann and Steger, 2007). Defined as the heritable 
changes in gene function that are not attributable to changes in DNA sequence, epigenetics 
involve biochemical modifications to DNA regulatory elements as well as to the tail regions 
of histone proteins (Maekawa and Watanabe, 2007). Lysine and arginine residues may be 
acetylated and methylated, with their effect being to activate or repress gene expression in 
the vicinity of that specific histone modification. Promoter regions of DNA are modified 
through the methylation of cytosine in CpG dinucleotides, resulting in the downregulation 
of those genes. Recent data suggest that these epigenetic modifications play a role in the 
development and progression of testicular germ cell tumors (TGCTs). This chapter will 
focus predominantly on adult TGCTs, along with their precursor carcinoma in situ (CIS), and 
will largely exclude the distinctive pediatric/prepubertal TGCTs. Many excellent reviews 
describing the classification of adult TGCTs exist (see Bahrami et al., 2007), and their content 
will not be duplicated here. Suffice it to say that the two main categories of TGCTs will be 
addressed in this chapter: the relatively undifferentiated seminomas, and the more 
differentiated non-seminomas (ranging from the less differentiated embryonal carcinomas 
to the highly differentiated yolk sac tumors, teratomas, and choriocarcinomas). Examination 
of histone modifications, histone modifying enzymes, genes exhibiting promoter DNA 
hypermethylation, and DNA methyltransferases in the context of CIS, seminomas, and non-
seminomas should increase our understanding of TGCT biology and potentially generate 
new clinical applications. 
2. Histone modifications and modifying enzymes 
Histone modifications greatly influence the transcription status of nearby genes in a highly 
specific manner. Lysine and arginine residues on the tails of histones H3 and H4 may be 
methylated to generate signatures that associate with active chromatin, such as the 
trimethylation of H3 lysine 4 (H3K4me3), or with repressed chromatin, such as the 
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dimethylation and trimethylation of histone H3 lysine 9 (H3K9me2 and H3K9me3). 
Histones may also be acetylated and deacetylated through histone acetyltransferases and 
histone deacetylases (HDACs), which correspond to active and repressed chromatin, 
respectively. Histone modifying enzymes that transfer methyl groups to target residues 
include EZH2, SUV39H1/2, and G9a, while enzymes that remove methyl groups include 
JMJD3 and UTX. 
2.1 H3K9 methylation 
Dimethylation and trimethylation of histone H3 lysine 9 (H3K9me2 and H3K9me3) are 
associated with transcriptional repression. These marks are established by the histone 
methyltransferases SUV39H1/2 and G9a, which are critical to establish and maintain 
regions of heterochromatin (Peters et al., 2001; Tachibana et al., 2007). When global H3K9 
methyl marks were examined in human CIS, Almstrup and colleagues found their presence 
to be very weak, revealing patterns similar to those in 20-40 week old normal fetal gonocytes 
(Almstrup et al., 2010). Interestingly, these marks were absent from the undifferentiated 
components of adult non-seminomatous embryonal carcinomas, but strongly detected in the 
undifferentiated seminomas (Almstrup et al., 2010). Godmann et al. reported the abundance 
of H3K9 methyl marks in both non-seminomas and seminomas, though they did not specify 
which nonseminomatous TGCTs they examined, nor their extent of differentiation 
(Godmann et al., 2009). In normal juvenile and adult mouse spermatogonia, the H3K9me2 
mark is notably absent from the undifferentiated cells that exhibit stem cell activity; its 
presence coincides with the lineage commitment to differentiation (Payne and Braun, 2006). 
H3K9me3, meanwhile, exhibits a distinct perinuclear distribution in the undifferentiated 
germ cells that shifts and broadens to abundant punctate foci in the differentiating Type A 
spermatogonia, localizing to heterochromatin-rich regions (Payne and Braun, 2006). While 
these patterns have not been extensively evaluated in human seminiferous tubules, it is 
tempting to speculate that the transformation from normal primordial germ 
cells/gonocytes to CIS, and then subsequently to seminomas, involves the progressive 
upregulation of histone methyltransferase activity that results in more abundant 
H3K9me2 and H3K9me3 marks.  
2.2 H3K27 methylation 
Trimethylation of histone H3 lysine 27 (H3K27me3) is associated with transcriptional 
repression; this mark is established by the histone methyltransferase EZH2, a member of the 
Polycomb group protein family (Cao and Zhang, 2004). Similar to H3K9 methyl marks, 
H3K27me3 distribution is weak in CIS and abundant in seminomas (Almstrup et al., 2010). 
Surprisingly, EZH2 is strongly detected in the cytoplasm of CIS. Given that this enzyme 
normally functions in the nucleus to methylate histones, its cytoplasmic accumulation likely 
reflects misregulation in CIS. EZH2 is absent from embryonal carcinomas, as is H3K27me3 
(Almstrup et al., 2010). 
2.3 H3K4 methylation 
Methylation of histone H3 lysine 4 (H3K4me1, H3K4me2, H3K4me3) is associated with 
transcriptional activation; H3K4me3 is established by the histone methyltransferase 
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Meisetz/PRDM9 (Hayashi et al., 2005). In contrast to the H3K9 and H3K27 methyl marks, 
H3K4me1 and H3K4me2/3 are abundant in CIS (Almstrup et al., 2010). Interestingly, the 
marks show opposing patterns in seminomas and non-seminomas (embryonal carcinomas), 
with H3K4me1 abundant in the former and weakly distributed in the latter, and H3K4me2/3 
exhibiting the reverse. The significance of this observation is not clear. H3K4me2/3 appears 
more broadly distributed than H3K4me1 in normal human adult spermatogenic cells 
(Almstrup et al., 2010). As with H3K9 methyl marks, Godmann and colleagues observe 
H3K4me3 in both non-seminomas and seminomas (Godmann et al., 2009). 
2.4 H4/H2AR3 methylation 
Symmetrical dimethylation of histones H4 and H2A at arginine 3 (H4R3me2 and 
H2AR3me2) is associated with transcriptional repression, and is established by the 
complex of BLIMP1 and PRMT5 (Ancelin et al., 2006). BLIMP1 is a transcriptional 
repressor with an N-terminal PR-SET domain, a C-terminal acidic domain, and five zinc-
finger domains; PRMT5 is a member of the protein arginine methyltransferase family. In 
normal fetal male germ cells of both mice and humans, H4R3me2 and H2AR3me2 marks 
are abundant in migratory primordial germ cells and gradually lost upon the transition to 
post-migratory gonocytes (Ancelin et al., 2006; Eckert, et al., 2008). In normal human adult 
testis, both marks are present in Type A spermatogonia, as well as round spermatids 
(Eckert et al., 2008). In CIS and seminomas, H4R3me2 and H2AR3me2 marks are 
abundant, with stronger signals detected in the seminomas. Heterogeneous, weak 
distribution of both marks is observed in some nonseminomatous TGCTs (embryonal 
carcinomas and teratomas). Dimethylation of H4R3 and H2AR3 is absent from 
choriocarcinomas. 
2.5 EZH2 
Enhancer of Zeste homolog 2 (EZH2) is a member of the Polycomb group protein family, 
functioning as a histone methyltransferase and adding methyl groups to H3K27 to 
generate H3K27me3. It is also considered to be an oncogene, shown to play a critical role 
in the development of breast cancer, prostate cancer, and malignant melanomas 
(Varambally et al., 2002; Bachmann et al., 2006). When examined in four cases of CIS, 64 
seminomas, and 36 non-seminomas (9 embryonal carcinomas, 3 teratocarcinomas, and 24 
mixed/combined TGCTs), EZH2 expression showed significant downregulation when 
compared to normal testicular tissue (~80 vs. ~18 in CIS/TGCTs, relative normalized 
units), as measured by quantitative real-time RT-PCR (Hinz et al., 2009). Surprisingly,  
this assessment of EZH2 mRNA conflicts with several observations of Almstrup  
and colleagues, who found a strong cytoplasmic distribution of EZH2 protein in CIS  
and abundant H3K27me3 marks in seminomas (Almstrup et al., 2010). These 
discrepancies could be due to the different methodologies used by the two groups (RT-
PCR with oligo primers vs. immunohistochemistry with antibodies), including the 
processing of the specimens. As EZH2 has previously been shown to be frequently 
expressed in TGCTs (Bracken et al., 2003), additional studies combining both quantitative 








Protein arginine methyltransferase 5 forms a complex with the BLIMP1 transcriptional 
repressor to symmetrically dimethylate H4R3 and H2AR3. As with the histone methyl 
marks it generates, PRMT5 is abundant in migratory primordial germ cells and is 
downregulated after the cells transition to post-migratory gonocytes (Ancelin et al., 2006; 
Eckert, et al., 2008). In normal human adult testis, PRMT5 is present in pachytene 
spermatocytes and round spermatids (Eckert et al., 2008). In CIS and seminomas, PRMT5 is 
strongly detected in the cytoplasm and nucleus, respectively. This enzyme is also observed 
in the cytoplasm of embryonal carcinomas and teratomas, but is absent from 
choriocarcinomas. The cytoplasmic localization of PRMT5 in many of the CIS and TGCT 
samples, compared to the nuclear distribution seen in normal fetal germ cells, might 
indicate misregulation occurring as a result of the oncogenic transformation events. 
2.7 JMJD3 and UTX 
Jumonji domain containing 3 (JMJD3; KDM6B) and ubiquitously transcribed tetratricopeptide 
repeat, X chromosome (UTX; KDM6A) are histone demethylase enzymes that remove 
methyl groups from H3K27me2 and H3K27me3. These proteins therefore functionally 
oppose EZH2. In normal human adult testis, JMJD3 is weakly detected in spermatogonia 
and round spermatids, with stronger distribution observed in spermatocytes (Almstrup et 
al., 2010). UTX exhibits a similar overall pattern, with less intensity seen at each germ cell 
stage. In CIS, neither JMJD3 nor UTX are observed, which is concordant with high levels of 
EZH2 detected in these samples (Almstrup et al., 2010). In seminomatous and 
nonseminomatous TGCTs, JMJD3 and UTX both exhibit weak distribution at levels similar 
to EZH2. 
2.8 HDAC1 
Histone deacetylase 1 removes acetyl groups from lysine residues that are localized at the 
N-terminal end of histones. HDAC1, as with other members of the HDAC family, induces 
transcriptional repression (De Ruijter et al., 2003). In normal human adult testis, HDAC1 
protein is observed in the nuclei of spermatogonia and Sertoli cells (Omisanjo et al., 2007). In 
both seminomatous and nonseminomatous TGCTs (embryonal carcinomas and teratomas), 
HDAC1 is consistently detected. 
2.9 Histone modifications in Sertoli cells 
HDAC1 and H3K9me3, as well as other histone modifying enzymes and modified tail 
residues, are present in normal human and mouse Sertoli cells (Omisanjo et al., 2007; Payne 
and Braun, 2006). Because Sertoli cells must maintain constant physical contact with germ 
cells at all stages inside each seminiferous tubule, the influence they have upon 
spermatogenesis is profound. Two essential growth factors that ensure the survival and 
maintenance of spermatogenic cells, and which are expressed by Sertoli cells, are Steel 
(KITL) and glial cell line-derived neurotrophic factor (GDNF). Steel activates the kit receptor 
(KIT) on differentiating spermatogonia in the postnatal testis, while GDNF activates 
associated receptors in undifferentiated spermatogonia: GDNF family receptor alpha 1 
(GFRA1) and ret tyrosine kinase (RET; Sette et al., 2000; Jing et al., 1996; Viglietto et al., 
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2000). Loss-of-function mutations of Steel and Gdnf in Sertoli cells deleteriously affect germ 
cell fate (Tajima et al., 1994; Meng et al., 2000). The loss of spermatogenic cells due to 
infertility or TGCTs also alters the epigenetic state of Sertoli cells, resulting in an increase in 
global histone H4 acetylation within the Sertoli cell nuclei of these human testes (Faure et 
al., 2003). In patients with seminomas and Sertoli cell-only syndrome, hyperacetylated 
histone H4 is observed in 70% of Sertoli cells. When Sertoli cell-specific gene targeting in 
mice inactivates Sin3a, which normally encodes an HDAC1-interacting protein, mutant 
testes exhibit the following: a significant reduction in spermatogonial stem cells, a 
progressive loss of differentiating spermatogonia, and a block in spermatid elongation, 
followed by extensive germ cell degeneration (Payne et al., 2010). Additionally, fewer 
teratomas are formed in a mouse tumor induction assay when donor germ cells from fetal 
Sin3a-mutant testes are transplanted into recipient adult testes (Payne et al, 2010). These 
results suggest that the epigenome in normal Sertoli cells supports a niche for 
spermatogonial stem cell activity, and provides a permissive microenvironment for the 
formation of adult TGCTs from fetal CIS. Further investigation on how Sertoli cells 
contribute to the development of TGCTs should increase our understanding of extrinsic 
factors that influence tumorigenesis. 
3. Genes exhibiting promoter DNA hypermethylation 
Numerous studies have shown that repetitive DNA within the human genome, consisting of 
Small Interspersed Nuclear Elements (SINEs), Long Interspersed Nuclear Elements (LINEs), 
and Long Terminal Repeats (LTRs), is globally hypomethylated in tumors (Ehrlich and 
Wang, 1981; Gama-Sosa et al., 1983; Dunn, 2003; Rodriguez et al., 2006). These repetitive 
elements are enriched in m5C relative to the whole genome within non-tumorigenic cells, 
but exhibit reduced methylation relative to the genome in many cancers, including those of 
the breast and ovary (Narayan et al., 1998; Qu et al., 1999). One interpretation of these 
findings is that the loss of methylation in repetitive DNA promotes genomic instability, 
resulting in deletions, translocations, and chromosomal rearrangements (Eden et al., 2003; 
Esteller, 2008). Hypomethylated centromeric regions, for example, can contribute to 
aneuploidy, and the reduced methylation of satellite sequences can lead to inappropriate 
recombination (Hatziapostolou and Iliopoulos, 2011). Active LINEs and microsatellite DNA 
instability have both been discovered in TGCTs (Bratthauer and Fanning, 1992; Huddart et 
al., 1995). Interestingly, a recent study found that while seminomatous tumors contain both 
LINE1 and Alu repeats (SINE family members) in a hypomethylated state, 
nonseminomatous tumors exhibit hypomethylated LINE1, but methylated Alu repeats 
(Ushida et al., 2011). 
In contrast, single-copy DNA regulatory elements of specific categories of genes undergo 
hypermethylation in many tumors (Estécio and Issa, 2011). CpG islands within promoter 
regions are usually unmethylated in non-tumorigenic cells, permitting gene transcription 
under the appropriate conditions (Suzuki and Bird, 2008). De novo methylation of CpG 
islands induces transcriptional silencing, often repressing tumor suppressor gene activity 
that creates optimal conditions for the onset and progression of most cancers. One of the 
first genes discovered to exhibit promoter DNA hypermethylation in tumor cells was RB, 
retinoblastoma (Sakai et al., 1991). To date, many genes identified as being susceptible to 
hypermethylation are known to suppress epithelial cancers, including those of the testis, 
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prostate, lung, and colon, as well as leukemias and lymphomas (Lind et al., 2007; Wali, 
2010). It is important to note that in the majority of TGCTs examined for hypermethylated 
gene promoters, CpG islands of most selected genes are methylated in non-seminomas, but 
are not appreciably methylated in seminomatous tumors (Koul et al., 2002; Honorio et al., 
2003, Lind et al., 2006). In support of this finding, global detection of m5C in CpG islands 
using a monoclonal antibody and immunohistochemistry revealed that the more 
differentiated TGCT histologies of non-seminomas (yolk sac tumors, teratomas, 
choriocarcinomas) exhibit hypermethylation, while the undifferentiated histology of 
seminomas do not show methylation (Wermann et al., 2010). Thus, it appears that in 
seminomas, both the repetitive DNA elements and the single-copy regulatory elements of 
genes are in an unmethylated state, highlighting a unique characteristic of these specific 
tumors. While many of the genes silenced by methylation are involved in DNA repair and 
the cell cycle checkpoint, others encode transcription factors, proteolytic enzymes, cell 
adhesion molecules, and proteins involved in various processes. Key genes that fall into 
each of these categories, identified to exhibit promoter DNA hypermethylation in TGCTs, 
will now be discussed in detail. 
3.1 DNA repair/cell cycle checkpoint genes 
RASSF1A 
This gene encodes the Ras association domain family 1 isoform A (RASSF1A). It is one of the 
most prevalent hypermethylated genes across all human cancers studied (Gordon and 
Baksh, 2011). In addition to TGCTs, RASSF1A is hypermethylated in the cancers of the 
breast, cervix, esophagus, brain, kidney, bladder, ovary, lung and skin (Pfeifer et al., 2002; 
Lusher et al., 2002; Koul et al., 2002; Honorio et al., 2003; Kuroki et al., 2003; Spugnardi et al., 
2003; Lind et al., 2006). RASSF1A tumor suppressor activity is important for DNA damage 
repair of double strand breaks and for pro-apoptotic mechanisms (Hamilton et al., 2009; 
Avruch et al., 2009). Four major studies detecting hypermethylated RASSF1A in untreated 
TGCTs have been published to date, with conflicting results for seminomas. Koul and 
colleagues reported that of the seminomatous and nonseminomatous TGCTs they 
examined, nearly all of the hypermethylated CpG islands were observed in non-seminomas 
(frequencies of ~100% in yolk sac tumors, ~45% in embryonal carcinomas, ~22% in 
teratomas, and ~9% in mixed/combined tumors); only 1 of 29 seminomas exhibited 
hypermethylated RASSF1A (Koul et al., 2002). In their examination of TGCTs, Honorio et al. 
found hypermethylated CpG islands in 15 of 18 (83%) non-seminomas, with frequencies of 
80% (4/5) in yolk sac tumors, 60% (3/5) in embryonal carcinomas, 100% (5/5) in teratomas, 
and 100% in two choriocarcinomas and one mixed tumor; 4 of 10 (40%) seminomas 
exhibited RASSF1A hypermethylation, distinguishing these results from the previous study 
(Honorio et al., 2003). Lind and colleagues, meanwhile, observed elevated methylation in 10 
of 35 (28.6%) nonseminomatous TGCTs and in 0 of 19 seminomas (Lind et al., 2006). The 
frequencies in the non-seminomas were: 50% (3/6) in yolk sac tumors, 37.5% (6/16) in 
embryonal carcinomas, 77.8% (7/9) in teratomas, and 100% in one choriocarcinoma. In 
contrast, Tian et al. recently reported that both seminomatous and nonseminomatous 
tumors contained equivalent frequencies of hypermethylated RASSF1A CpG islands 
(~78.6%), with an average of 13/16 CpG sites in a methylated state as measured by sodium 
bisulfite sequencing (Tian et al., 2011). In an earlier study, Kawakami and colleagues did not 
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detect the hypermethylation of RASSF1A, or any other gene they examined, in any of the 
TGCTs under investigation (Kawakami et al., 2003). Thus, from all of these studies it 
appears that RASSF1A is hypermethylated at a frequency of up to 100% in yolk sac tumors, 
teratomas, choriocarcinomas, and up to 60% in embryonal carcinomas, but exhibits 
divergent methylation patterns in seminomas. Further characterization of RASSF1A in 
seminomas is needed to address these discrepancies. Interestingly, when Koul and 
colleagues examined 39 cisplatin-resistant and 31 cisplatin-sensitive non-seminomas, 
RASSF1A exhibited a much higher frequency of methylation in the cisplatin-resistant group 
(52%) than in the cisplatin-sensitive group (28%), though the sample size was too small for 
statistical significance (Koul et al., 2004). The methylation status of the RASSF1A promoter 
might therefore be a useful prognostic indicator of nonseminomatous tumor sensitivity to 
cisplatin, and could allow for the adjustment of chemotherapy treatment strategy 
accordingly. Finally, it has been shown that hypermethylated RASSF1A CpG islands are 
detected in the cell-free circulating serum DNA of TGCT patients at a frequency of ~47% 
(Ellinger et al., 2009). This method of detection could provide an additional benefit to 
existing parameters in the clinic. 
MGMT 
This gene encodes O-6-methylguanine-DNA methyltransferase (MGMT), which provides 
defense against the mutagenic effects of O-6-methylguanine (alkylation adduct) in DNA and 
potential G-to-A transition mutations. MGMT repairs the O-6 position of guanine in DNA 
by transferring the alkyl group from this position to a cysteine residue within the structure 
of the protein (Mitra, 2007). The MGMT promoter is hypermethylated in glioblastomas, 
hepatocellular carcinomas, colorectal, esophageal, and lung cancers, as well as in TGCTs 
(Cao et al., 2009; Zhang et al., 2003; Ahlquist et al., 2008; Baumann et al., 2006; Wolf et al., 
2001; Smith-Sørensen et al., 2002; Koul et al., 2002; Honorio et al., 2003; Koul et al., 2004). 
Smith-Sørensen and colleagues identified hypermethylated CpG islands in both 
seminomatous tumors (24%, 8/33) and nonseminomatous tumors (69%, 24/35), while the 
groups of Koul and Honorio found MGMT hypermethylation only in non-seminomas 
(frequencies of ~25% in yolk sac tumors, ~45% in embryonal carcinomas, ~30% in teratomas, 
and ~9% in mixed/combined tumors for Koul et al.); 44% of non-seminomas exhibited 
hypermethylated MGMT for Honorio and colleagues (Smith-Sørensen et al., 2002; Koul et 
al., 2002; Honorio et al., 2003). In contrast to RASSF1A, Koul et al. found that MGMT was 
hypermethylated more often in cisplatin-sensitive non-seminomas (31%) than in cisplatin-
resistant tumors (13%), though the P-value was not significant (Koul et al., 2004). Compared 
to the hypermethylation of RASSF1A and all other genes examined in TGCTs, MGMT 
exhibited the highest frequency of hypermethylation in seminomas (11%, 8 of 72 combined 
from all three studies). Given the overall small sample sizes and discrepancies reported 
among the groups, it would be worth conducting a larger study examining RASSF1A and 
MGMT hypermethylation in seminomas to more accurately conclude whether the CpG 
islands of these genes might be the exception to the overall trend of unmethylated cytosine 
in seminoma DNA. 
BRCA1 
Breast cancer 1 encodes a multi-faceted protein involved in numerous cellular functions: 
DNA damage repair, cell cycle checkpoint, centrosome duplication, transcriptional 
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regulation, and many others (Deng and Brodie, 2000). Hypermethylated BRCA1 is observed 
in a variety of cancers, including breast, ovary, bladder, lung, and testis (Rice et al., 2000; 
Bianco et al., 2000; Cabello et al., 2011; Wang et al., 2008; Koul et al., 2002). Koul and 
colleagues reported that of the seminomatous and nonseminomatous TGCTs they 
examined, nearly all of the hypermethylated CpG islands were observed in non-seminomas 
(frequencies of ~49% in yolk sac tumors, and equivalent percentages in embryonal 
carcinomas, teratomas, and mixed/combined tumors, 20-24%); only 1 of 29 seminomas 
exhibited hypermethylated BRCA1 (Koul et al., 2002). No differences were observed 
between cisplatin-sensitive (31%) and –resistant (30%) non-seminomas with respect to CpG 
island methylation (Koul et al., 2004). 
FANCF 
Fanconi anemia, complementation group F encodes a DNA repair protein that supports post-
replication repair, cell cycle checkpoint function, and maintenance of normal chromosome 
stability (Léveillé et al., 2004). FANCF is hypermethylated in cervical and ovarian cancers, as 
well as TGCTs (Narayan et al., 2004; Taniguchi et al., 2003; Koul et al., 2004). Koul and 
colleagues examined CpG island methylation only in nonseminomatous tumors, and found 
the overall frequency to be 5.7%. No differences were observed between cisplatin-sensitive 
(7%) and –resistant (6%) non-seminomas with respect to hypermethylated FANCF (Koul et 
al., 2004). 
XPA 
Xeroderma pigmentosum, complementation group A encodes a zinc finger protein that 
participates in the initial step of DNA excision repair (de Vries and van Steeg, 1996). XPA 
guards against the harmful effects of UV-B radiation and chemical compounds that would 
otherwise impair DNA replication and RNA transcription. While XPA expression is 
diminished in some colorectal cancers, CpG methylation has only been observed in one 
nonseminomatous TGCT (Yu et al., 2006; Lind et al., 2006). Lind and colleagues found that 
one of 6 yolk sac tumors exhibited hypermethylated XPA; no methylation was detected in 
any of 16 embryonal carcinomas, 9 teratomas, 1 choriocarcinoma, 3 mixed/combined 
tumors, and 20 seminomas (Lind et al., 2006). Thus, it appears that XPA is not appreciably 
methylated in either seminomas or non-seminomas. 
MLH1 
mutL homolog 1 (a homolog of the E. coli DNA mismatch repair gene mutL) encodes a protein 
that forms a component of the post-replicative DNA mismatch repair system. MLH1 is 
involved in DNA damage signaling, inducing cell cycle arrest and apoptosis under certain 
conditions (Buermeyer et al., 1999). The MLH1 promoter is hypermethylated in numerous 
cancers, including colorectal, gastric, and endometrial carcinomas, and tumors of the breast, 
ovary, and testis (Herman et al., 1998; Leung et al., 1999; Esteller et al., 1998; Murata et al., 
2002; Strathdee et al., 1999; Koul et al., 2002; Olasz et al., 2005). Koul and colleagues reported 
that of the seminomatous and nonseminomatous TGCTs they examined, nearly all of the 
hypermethylated CpG islands were observed in non-seminomas (no methylation detected 
in yolk sac tumors or teratomas, and frequencies of <10% in embryonal carcinomas and 
mixed/combined tumors); only 1 of 29 seminomas exhibited hypermethylated MLH1 (Koul 
et al., 2002). Olasz et al. found an overall methylation frequency of 21.6% in the TGCTs they 
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examined, yet only 1 in 15 samples from refractory tumors showed CpG hypermethylation 
(Olasz et al., 2005). Unlike what has been observed in familiar colorectal cancer, no 
correlation exists between MLH1 methylation status and microsatellite instability in TGCTs 
(Herman et al., 1998; Olasz et al., 2005). No relationship is seen between the clinical outcome 
of TGCTs and MLH1 hypermethylation, dampening its prospect as a potential biomarker. 
APC 
adenomatous polyposis coli encodes a tumor suppressor protein that antagonizes Wnt 
signaling. APC is also critical for cell migration and adhesion, transcriptional activation, 
DNA repair, and apoptosis (Senda et al., 2007). Hypermethylated APC is observed in many 
cancers, including colorectal, esophageal, breast, lung, prostate, and testis (Hiltunen et al., 
1997; Kawakami et al., 2000; Virmani et al., 2001; Yegnasubramanian et al., 2004; Koul et al., 
2002; Honorio et al., 2003). Koul and colleagues found an overall CpG methylation 
frequency of 9.8% in the nonseminomatous TGCTs they examined (~100% in yolk sac 
tumors, ~12% in teratomas, and ~3% in mixed/combined tumors; no methylation seen in 
embryonal carcinomas or seminomas), while Honorio et al. detected APC hypermethylation 
in 29% of non-seminomas (Koul et al., 2002; Honorio et al., 2003). No differences were 
observed between cisplatin-sensitive (24%) and –resistant (29%) non-seminomas with 
respect to hypermethylated APC (Koul et al., 2004). It was also recently shown that 
hypermethylated CpG islands of APC are detected in the cell-free circulating serum DNA of 
TGCT patients at a frequency of ~58% (Ellinger et al., 2009). 
FHIT 
fragile histidine triad gene encodes an enzyme, diadenosine 5',5'''-P1,P3-triphosphate 
hydrolase, that is involved in purine metabolism. It also promotes genomic integrity 
through DNA damage response and DNA repair mechanisms (Saldivar et al., 2010). FHIT is 
one of the most frequent targets of allele deletion in tumors, and is hypermethylated in 
cancers of the lung, cervix, liver, and testis (Hsu et al., 2007; Ki et al., 2008; Iyer et al., 2010; 
Koul et al., 2002; Honorio et al., 2003). Koul and colleagues observed FHIT 
hypermethylation at an overall frequency of 6.5% in non-seminomas (~49% in yolk sac 
tumors, ~8% in embryonal carcinomas, ~2% in teratomas, and ~3% in mixed/combined 
tumors), while Honorio et al. detected CpG methylation in 29% of nonseminomatous 
tumors (Koul et al., 2002; Honorio et al., 2003). No differences were observed between 
cisplatin-sensitive (7%) and –resistant (6%) non-seminomas with respect to hypermethylated 
FHIT (Koul et al., 2004). 
CDKN2A 
cyclin-dependent kinase inhibitor 2A generates multiple transcript variants that differ in their 
first exons. One of the transcripts contains an alternate open reading frame (ARF), yielding a 
protein that stabilizes tumor suppressor p53 through the sequestration of MDM2 (Gjerset, 
2006). CDKN2A can also induce cell cycle arrest in G1 and G2, and promote apoptosis. 
CDKN2A hypermethylation in the forms of p14(ARF) and p16(INK) has been detected in 
numerous cancers, including those of the colon, stomach, kidney, uterus, ovary, and testis 
(Esteller et al., 2001; Chaubert et al., 1997). Variable results have been shown for TGCTs. 
Chaubert and colleagues reported the presence of hypermethylated CDKN2A in 13 of 26 
(50%) TGCTs using the method of PCR amplification after HpaII enzyme digestion 
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(Chaubert et al., 1997). The groups of Smith-Sørensen, Honorio, and Kawakami, in contrast, 
were not able to detect methylated CpG islands of CDKN2A when examined by 
methylation-specific PCR (Smith-Sørensen et al., 2002; Honorio et al., 2003; Kawakami et al., 
2003). Differing experimental strategies might explain this discrepancy. Hypermethylation 
of p14(ARF) and p16(INK) was recently observed in the cell-free circulating serum DNA of 
TGCT patients at a frequency of ~53% (Ellinger et al., 2009). 
3.2 Transcription factor genes 
NANOG 
This gene encodes an important regulator of pluripotency maintenance in the inner cell 
mass of blastocyst-stage embryos and in undifferentiated embryonic stem cells. NANOG 
prevents differentiation into mesoderm by interacting with SMAD1 and blocking the 
recruitment of co-activators in that signaling pathway (Suzuki et al., 2006). Migratory 
primordial germ cells express NANOG, but upon the differentiation of male germ cells into 
fetal gonocytes and neonatal spermatogonia, NANOG is downregulated (Gaskell et al., 
2004). Thus, normal juvenile and adult male germ cells do not express NANOG. 
Interestingly, Nettersheim et al. detected hypomethylated NANOG, and corresponding 
protein, in all seminomas and embryonal carcinomas (undifferentiated non-seminomas) 
they obtained from TGCT patients (Nettersheim et al., 2011). In contrast, all differentiated 
non-seminomas (yolk sac tumors, teratomas, and choriocarcinomas) exhibited CpG 
hypermethylation and an absence of NANOG protein. Similarly, normal adult 
spermatogonia contain hypermethylated NANOG, supporting the prevailing hypothesis 
that seminomas are derived from gonocyte precursors in the fetal gonad (Nettersheim et al., 
2011). Thus, differences within the state of TGCT differentiation correlate with the extent of 
NANOG hypermethylation. 
HIC1 
hypermethylated in cancer 1 encodes a transcriptional repressor protein that functionally 
interacts with p53 to suppress the development of cancer throughout aging (Chen et al., 
2005). The HIC1 promoter is hypermethylated in many cancers, including those of the 
breast, cervix, and testis (Fujii et al., 1998; Dong et al., 2001; Koul et al., 2002). Koul and 
colleagues observed HIC1 hypermethylation only in non-seminomas (frequencies of ~100% 
in yolk sac tumors, ~35% in embryonal carcinomas, ~21% in teratomas, and ~9% in 
mixed/combined tumors). None of 29 seminomas exhibited hypermethylated HIC1 (Koul et 
al., 2002). HIC1 also exhibited a much higher frequency of methylation in the cisplatin-
resistant group (47%) than in the cisplatin-sensitive group (24%), though the sample size 
was too small for statistical significance (Koul et al., 2004). Like RASSF1A, the methylation 
status of the HIC1 promoter could be a useful prognostic indicator of nonseminomatous 
tumor sensitivity to cisplatin. 
HOXA9 
homeobox A9 encodes a transcription factor that regulates differentiation and morphogenesis, 
and is important for hematopoiesis (Lawrence et al., 1997). Hypermethylated HOXA9 has 
been reported for ovarian carcinomas, oral squamous cell carcinomas, lung cancer, liver 
cancer, and TGCTs (Wu et al., 2007; Guerrero-Preston et al., 2011; Hwang et al., 2011; Feng et 
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al., 2010; Lind et al., 2006). Lind and colleagues observed HOXA9 hypermethylation only in 
nonseminomatous tumors, in 9 of 35 samples (detected in yolk sac tumors, teratomas, and 
one choriocarcinoma; Lind et al., 2006). 
HOXB5 
homeobox B5 encodes a transcription factor involved in lung and gut development, 
regulating differentiation and morphogenesis, and providing specific positional identities 
on the anterior-posterior axis (Volpe et al., 1997; Fu et al., 2003). Hypermethylated HOXB5 
has been reported for ovarian carcinomas and TGCTs (Wu et al., 2007; Lind et al., 2006). 
Lind and colleagues observed HOXB5 hypermethylation only in nonseminomatous tumors, 
in 5 of 35 samples (detected exclusively in teratomas; Lind et al., 2006). 
RARB 
retinoic acid receptor, beta encodes a nuclear receptor that binds to retinoic acid, 
heterodimerizing with the retinoid x receptor and regulating transcriptional activity though 
retinoic acid response elements located in target genes (Dollé, 2009). RARB 
hypermethylation has been detected in numerous cancers, including those of the cervix, 
prostate, lung, bladder, and testis (Narayan et al., 2003; Singal et al., 2004; Feng et al., 2008; 
Cabello et al., 2011; Koul et al., 2002; Honorio et al., 2003). The groups of Koul and Honorio 
found RARB hypermethylation only in non-seminomas (frequencies of ~49% in yolk sac 
tumors, ~15% in embryonal carcinomas, and ~5% in teratomas for Koul et al.); only 5% of 
non-seminomas exhibited hypermethylated RARB for Honorio and colleagues (Koul et al., 
2002; Honorio et al., 2003). Koul et al. also found that RARB was hypermethylated more 
often in cisplatin-sensitive non-seminomas (14%) than in cisplatin-resistant tumors (0%), 
with a P-value of 0.05 (Koul et al., 2004). 
EMX2 
empty spiracles homeobox 2 encodes a transcription factor that regulates neuroblast 
proliferation, migration and differentiation, patterns the forebrain, and defines cortical 
territories (Cecchi, 2002). In the urogenital system, EMX2 is expressed in epithelial cells and 
is negatively regulated by HOXA10 (Troy et al., 2003). Hypermethylated EMX2 has been 
reported for lung cancer and TGCTs (Okamoto et al., 2010; Lind et al., 2006). Lind and 
colleagues found that one of 6 yolk sac tumors exhibited hypermethylated EMX2; no 
methylation was detected in any of 16 embryonal carcinomas, 9 teratomas, 1 
choriocarcinoma, 3 mixed/combined tumors, and 20 seminomas (Lind et al., 2006). Thus, it 
appears that EMX2 is not appreciably methylated in either seminomas or non-seminomas. 
MSX1 
msh homeobox 1 encodes a member of the muscle segment homeobox gene family. 
Functioning as a transcriptional repressor, MSX1 influences limb pattern formation and 
craniofacial development (Alappat et al., 2003). Hypermethylated MSX1 has been reported 
for acute lymphoblastic leukemia, and cancers of the breast, lung, colon, prostate, and testis 
(Dunwell et al., 2009; Shames et al., 2006; Lind et al., 2006). Lind and colleagues found that 
one of 6 yolk sac tumors exhibited hypermethylated MSX1; no methylation was detected in 
any of 16 embryonal carcinomas, 9 teratomas, 1 choriocarcinoma, 3 mixed/combined 
tumors, and 20 seminomas (Lind et al., 2006). Thus, it appears that MSX1 is not appreciably 
methylated in either seminomas or non-seminomas. 
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runt-related transcription factor 3 encodes a member of the runt domain-containing family of 
transcription factors that binds to core sequences found in a number of enhancers and 
promoters (Otto et al., 2003). The RUNX3 promoter is hypermethylated in many cancers, 
including those of the lung, liver, colon, bladder, breast, and testis (Li et al., 2004; Xiao and 
Liu, 2004; Goel et al., 2004; Kim et al., 2005; Hwang et al., 2007; Kato et al., 2003; Lind et al., 
2006). Interestingly, Kato and colleagues reported that while 8 of 10 infantile yolk sac 
tumors exhibited RUNX3 hypermethylation (specimens obtained from pediatric patients), 0 
of 12 adult nonseminomatous TGCTs contained methylated RUNX3, despite 7 of the 11 
mixed/combined TGCTs containing yolk sac tumors (Kato et al., 2003). Similarly, Lind et al. 
found that only one of 6 adult yolk sac tumors exhibited hypermethylated RUNX3, and no 
methylation was detected in any of 49 other adult non-seminomas (16 embryonal 
carcinomas, 9 teratomas, 1 choriocarcinoma, 3 mixed/combined tumors, and 20 seminomas; 
Lind et al., 2006). These observations strongly suggest that distinct epigenetic dysregulatory 
mechanisms occur in pediatric, but not adult yolk sac tumors, and that RUNX3 is not 
appreciably methylated in either seminomatous or nonseminomatous adult TGCTs. 
3.3 Proteolysis genes 
PRSS21 
protease, serine, 21 encodes a member of the trypsin family of serine proteases that uses the 
hydroxyl group of serine to cleave target peptide bonds involving the carboxyl group of 
lysine or arginine (Rawlings and Barrett, 1994). PRSS21 is thought to regulate proteolytic 
events associated with male germ cell maturation, as it is expressed highly only in normal 
testis, and its hypermethylation and transcriptional repression have been observed in 
TGCTs (Manton et al., 2005; Kempkensteffen et al., 2006). Manton and colleagues reported 
that the majority of CpG islands were methylated in both seminomatous (86%, 3 samples) 
and nonseminomatous (87%, 5 samples) tumors (Manton et al., 2005). While 
Kempkensteffen et al. found the overall level of hypermethylation lower in seminomas than 
in non-seminomas, the levels were still significantly higher when compared to normal 
testicular tissue (Kempkensteffen et al., 2006). Thus, PRSS21 appears to show the most 
extensive hypermethylation of any gene examined to date in seminomas, and might 
therefore be a useful biomarker for early detection of these tumors in the clinic, especially if 
detected in the cell-free circulating serum DNA. 
TIMP3 
tissue inhibitor of metalloproteinase 3 encodes a protein that inhibits matrix metalloproteinases, 
enzymes that degrade components of the extracellular matrix (Apte et al., 1995). TIMP3 
hypermethylation has been detected in numerous cancers, including those of the kidney, 
colon, breast, brain, lung, and testis (Esteller et al., 2001; Koul et al., 2002). Koul and 
colleagues, however, observed an overall frequency of hypermethylation of just 3.3% in 
non-seminomas, with detection of methylated CpG islands limited to embryonal carcinomas 
and mixed/combined tumors (Koul et al., 2002). No hypermethylation was seen in 
seminomas. Therefore, compared to other genes, TIMP3 does not appear to be as extensively 
hypermethylated in non-seminomas. 
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3.4 Cell adhesion genes 
CDH1 
cadherin 1 encodes a calcium dependent cell-cell adhesion glycoprotein highly expressed in 
epithelial tissues, E-cadherin, that is comprised of five extracellular cadherin repeats, a 
transmembrane region, and a highly conserved cytoplasmic tail. Mutations in CDH1 that 
disrupt the adhesive properties of E-cadherin occur in some breast and gastric carcinomas 
(Hirohashi, 1998). CDH1 hypermethylation is also detected in many cancers, including 
leukemia and those of the esophagus, breast, prostate, and testis (Esteller et al., 2001; Koul et 
al., 2002; Honorio et al., 2003). Koul and colleagues reported that of the seminomatous and 
nonseminomatous TGCTs they examined, the majority of hypermethylated CpG islands 
were observed in non-seminomas (frequencies of <10% in embryonal carcinomas, teratomas, 
and mixed/combined tumors); only 1 of 29 seminomas exhibited hypermethylated CDH1 
(Koul et al., 2002). Honorio et al. detected an overall methylation frequency of 11% in non-
seminomas (Honorio et al., 2003). No differences were observed between cisplatin-sensitive 
(3%) and –resistant (6%) non-seminomas with respect to hypermethylated CDH1 (Koul et 
al., 2004). 
CDH13 
cadherin 13 encodes a calcium dependent cell-cell adhesion glycoprotein highly expressed in 
heart tissues, H-cadherin, that is comprised of five extracellular cadherin repeats, a 
transmembrane region, but unlike other cadherins, lacks the highly conserved cytoplasmic 
tail. The CDH13 promoter is hypermethylated in numerous cancers, including chronic 
myeloid leukemia and those of the breast, lung, bladder, and testis (Roman-Gomez et al., 
2003; Toyooka et al., 2001; Maruyama et al., 2001; Honorio et al., 2003; Lind et al., 2006). 
Honorio and colleagues reported an overall frequency of hypermethylated CDH13 in 12% of 
non-seminomas, while Lind et al. detected hypermethylation in 9% of nonseminomatous (2 
of 16 embryonal carcinomas; 0 of 9 teratomas) and 6% (1/17) of seminomatous TGCTs 
(Honorio et al., 2003; Lind et al., 2006). Despite the small sample size, CDH13 
hypermethylation was observed in the more undifferentiated TGCTs and not in the more 
highly differentiated non-seminomas, distinguishing this gene from most others that have 
been described here. 
3.5 Genes involved in other processes 
SCGB3A1 (extracellular/cytokine) 
secretoglobin, family 3A, member 1 encodes a secreted protein, formerly called high in normal 1 
(HIN1), which has tumor suppressor activity, although the exact function of the protein is 
unknown. SCGB3A1 is highly expressed in the lung and trachea of humans and mice, with 
additional expression in a species-dependent manner (Tomita and Kimura, 2008). 
Hypermethylated SCGB3A1 has been reported for cancers of the nasopharynx, breast, lung, 
prostate, pancreas, stomach, and testis, among others (Wong et al., 2003; Fackler et al., 2003; 
Krop et al., 2004; Gong et al., 2011; Lind et al., 2006). Lind and colleagues observed SCGB3A1 
hypermethylation in 19 of 35 non-seminomas (frequencies of ~100% in choriocarcinomas, 
~75% in teratomas, ~47% in yolk sac tumors, and ~35% in embryonal carcinomas); no 
methylation was detected in seminomas (Lind et al., 2006). 
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SORBS1 (glucose transport) 
sorbin and SH3 domain containing 1 encodes a protein involved in tyrosine phosphorylation of 
c-Abl, via an interaction with the insulin receptor, and is required for insulin-stimulated 
glucose transport (Lin et al., 2001). Lind and colleagues reported SORBS1 hypermethylation 
in 1 of 20 seminomatous TGCTs examined, with no detection in non-seminomas (0/35; Lind 
et al., 2006). Given the sample size, additional studies will be necessary to conclusively 
determine whether this gene is a useful biomarker for TGCTs.  
GSTP1 (metabolic process) 
glutathione S-transferase, pi 1 encodes an enzyme important for detoxification by catalyzing 
the conjugation of hydrophobic and electrophilic compounds with reduced glutathione 
(Strange et al., 2001). The GST family is categorized into four classes: alpha, mu, pi, and 
theta. GSTP1 hypermethylation is observed in many cancers, including those of the liver, 
kidney, breast, lung, esophagus, brain, and colon (Esteller et al., 2001). The groups of 
Kawakami and Honorio did not find hypermethylated GSTP1 in any of their seminomatous 
or nonseminomatous TGCT samples, but Koul et al. reported GSTP1 hypermethylation in 1 
of 29 seminomas (none in non-seminomas) and Ellinger et al. detected CpG island 
methylation in the cell-free circulating serum DNA of TGCT patients at a frequency of ~25% 
(Koul et al., 2002; Kawakami et al., 2003; Honorio et al., 2003; Ellinger et al., 2009). The TGCT 
patients had seminomas (N=36) as well as non-seminomas (N=37), and the hypermethylation 
frequency observed by Ellinger and colleagues was equivalent between the two groups 
(Ellinger et al., 2009). Clearly, additional studies will be necessary to determine why 
discrepancies exist between not observing GSTP1 hypermethylation in the majority of TGCT 
samples and frequently observing it in the cell-free serum DNA of TGCT patients. 
PTGS2 (oxidation-reduction) 
prostaglandin-endoperoxidase synthase 2 encodes a key enzyme in prostaglandin biosynthesis, 
also known as COX2, which acts as both a dioxygenase and a peroxidase. Two isozymes of 
PTGS exist, the constitutive PTGS1 and the inducible PTGS2, which differ in their regulation 
of expression and tissue distribution. This gene encodes the inducible isozyme, and is 
misregulated in many cancers (Rizzo, 2011). Hypermethylated PTGS2 has been reported for 
gliomas, gastric carcinomas, prostate cancer, and breast cancer, among others (Uhlmann et 
al., 2003; Yu et al., 2003; Yegnasubramanian et al., 2004; Chow et al., 2005). Ellinger and 
colleagues detected PTGS2 CpG island hypermethylation in the cell-free circulating serum 
DNA of TGCT patients at a frequency of ~45%; no differences were observed between 
patients with seminomas and those with non-seminomas (Ellinger et al., 2009). It remains to 
be seen whether a similar frequency of hypermethylation is observed directly in TGCT 
specimens. Currently, the cell-free serum-based detection of hypermethylated PTGS2, like 
RASSF1A, APC, CDKN2A and GSTP1, could provide additional benefits to existing 
parameters in the clinic. 
NME2 (phosphorylation) 
non-metastatic cells 2, protein (NM23B) expressed in (official gene name) encodes a protein 
that, together with the product of NME1, forms the hexamer nucleoside diphosphate 
kinase (Postel et al., 2002). Koul and colleagues reported NME2 CpG hypermethylation in 
one embryonal carcinoma sample (Koul et al., 2002), but no other known observations in 
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TGCTs or other cancers have been published, raising the uncertainty over the significance 
of this discovery. 
4. DNA methyltransferases 
DNA methylation is established by the coordinated activity of enzymes known as DNA 
methyltransferases (DNMTs). The mammalian DNMT family consists of DNMT1, 
DNMT3A, DNMT3B, and DNMT3L, and is responsible for the generation, acquisition, and 
maintenance of methylated cytosines residing in CpG dinucleotides (Jurkowska et al., 2010). 
DNMT3A and DNMT3B are de novo methyltransferases, while DNMT1 is a maintenance 
methyltransferase, required to preserve the methylated status of the DNA. Levels of DNMTs 
are increased in numerous cancers, accounting for the hypermethylation of CpG islands 
observed in the promoters of many genes. Thus, DNMTs are promising targets for the 
design of new anti-cancer therapeutics. 
4.1 DNMT1 
DNA methyltransferase 1 is responsible for the maintenance of the DNA methylation status 
in CpG dinucleotides (Bestor et al., 1988). Hypermethylation of CpG islands in gene 
promoters, as Section 3 in this chapter extensively describes, is associated with the 
transcriptional silencing of tumor suppressors and other genes in many cancers, including 
TGCTs. Omisanjo and colleagues examined the expression of DNMT1 mRNA and protein in 
TGCTs to determine whether DNMT1 is upregulated. In normal human adult testis, DNMT1 
mRNA is expressed in spermatogonia, pachytene spermatocytes, and round spermatids, as 
measured by in situ hybridization; the protein is nuclear in spermatogonia, cytoplasmic in 
round spermatids, and interestingly, is not detected in pachytene spermatocytes (Omisanjo 
et al., 2007). In non-seminomas (8 embryonal carcinomas and 8 teratomas), both mRNA and 
protein are detected, with a stronger signal observed in the embryonal carcinomas. Neither 
mRNA nor protein are detected in seminomas (0/16; Omisanjo et al., 2007). These 
differential TGCT expression patterns of DNMT1 were also found using RNA microarray 
analysis and quantitative real-time RT-PCR, showing significantly upregulated transcript 
levels in embryonal carcinomas, but low levels in seminomas (Biermann et al., 2007). In 
contrast, semi-quantitative RT-PCR analysis performed by Ishii and colleagues showed no 
difference in DNMT1 expression between control tissue and either seminomatous or 
nonseminomatous TGCTs (Ishii et al., 2007). DNA methyltransferase inhibitors, such as 5-
aza-2’-deoxycytidine, have been shown to reactivate silenced tumor suppressor genes in 
treated cancer cells, implying that DNMTs are both necessary and sufficient to maintain 
hypermethylated CpG islands in many tumors. 
4.2 DNMT3A 
DNA methyltransferase 3A is responsible for the de novo transfer of methyl groups to CpG 
dinucleotides. DNMT3A catalyzes the transfer of a methyl group from S-adenosyl-
methionine to the 5’ position of cytosine in DNA (Okano et al., 1999). Studies in mice have 
shown that DNMT3A is essential for imprinting, as well as for spermatogenesis (Kaneda et 
al., 2004). Ishii and colleagues recently examined the expression of DNMT3A mRNA and 
protein in TGCTs, known to exhibit hypermethylated CpG islands in numerous genes, to 
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determine whether DNMT3A is upregulated. Semi-quantitative RT-PCR analysis revealed 
that DNMT3A and its isoform, DNMT3A2, are significantly overexpressed in seminomas as 
well as non-seminomas (embryonal carcinomas, teratomas, choriocarcinomas, yolk sac 
tumors; Ishii et al., 2007). Protein analysis by immunoblot revealed that the DNMT3A2 
isoform is exhibited several times higher than control levels in both seminomatous and 
nonseminomatous TGCTs (Ishii et al., 2007). Thus, the upregulation of DNMT3A2 appears 
to generate higher amounts of protein, and seems to be tumor cell-specific. Ishii et al. then 
examined the methylation levels of CpG-rich regions in the DNMT3A gene, and found more 
unmethylated DNMT3A CpG dinucleotides in seminomas than in adjacent non-tumor tissue 
(Ishii et al., 2007). Overexpression of DNMT3A in TGCTs therefore appears to result from 
the hypomethylation of CpG islands in key regulatory regions, allowing inappropriate 
transcription to occur. 
4.3 DNMT3B 
DNA methyltransferase 3B is responsible for the de novo transfer of methyl groups to CpG 
dinucleotides. DNMT3B catalyzes the transfer of a methyl group from S-adenosyl-
methionine to the 5’ position of cytosine in DNA (Okano et al., 1999). Beyrouthy and 
colleagues recently examined the protein expression of DNMT3B in embryonal carcinoma 
cell lines to determine whether they exhibit higher protein levels than in normal tissues or 
somatic tumors. Western blot analysis revealed that DNMT3B is significantly overexpressed 
in embryonal carcinoma cell lines when compared to all other cell types (Beyrouthy et al., 
2009). Three earlier microarray studies reported upregulated DNMT3B mRNA in non-
seminomas (primarily embryonal carcinomas), but not in seminomas when compared to 
non-cancerous controls (Almstrup et al., 2005; Korkola et al., 2005; Skotheim et al., 2005). In 
contrast, Ishii et al. found no significant difference in DNMT3B expression between control 
tissue and either seminomatous or nonseminomatous TGCTs, which were mostly teratomas, 
choriocarcinomas, and yolk sac tumors (Ishii et al., 2007). This difference in TGCT sample 
type could explain the discrepancy in the results; clearly DNMT3B appears to be 
overexpressed in embryonal carcinomas. Furthermore, knockdown of DNMT3B reverses 5-
aza-2’-deoxycytidine hypersensitivity in both cisplatin-sensitive and cisplatin-resistant 
embryonal carcinoma cells (Beyrouthy et al., 2009). While cisplatin sensitivity itself is not 
affected by DNMT3B expression, 5-aza-2’-deoxycytidine hypersensitivity in embryonal 
carcinoma cells appears to be dependent on DNMT3B expression, regardless of whether the 
cells are sensitive or resistant to cisplatin. 
5. Clinical applications 
When compared to many other cancers, a remarkable aspect in the majority of TGCTs is the 
high curability rate using cisplatin-based chemotherapy in combination with radiation 
therapy. However, up to 30% of metastatic germ cell tumors of the testis are refractory to 
cisplatin treatment and can lead to mortality. As discussed earlier, hypermethylation of CpG 
islands in the promoters of two genes, RASSF1A and HIC1, has been observed in cisplatin-
resistant tumors at a frequency of approximately 50%, while promoter hypermethylation for 
MGMT and RARB has been detected at higher frequencies in cisplatin-sensitive vs. 
chemoresistant tumors (Koul et al., 2004). Recent investigation into the use of DNA 
demethylating agent 5-azacytidine in TCam-2 cells as a method to decrease cisplatin 
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resistance has shown promising results (Wermann et al., 2010). Drugs that target DNMTs are 
currently in use in clinical trials, such as 5-aza-2’-deoxycytidine for treating myelodysplastic 
syndromes (Müller-Thomas et al., 2009), and newer drugs are under development. 
6. Conclusion 
A greater understanding of the role of histone modifications, histone modifying enzymes, 
genes exhibiting promoter DNA hypermethylation, and DNA methyltransferases in adult 
TGCTs should yield potentially useful biomarkers to aid in early detection, as well as new 
methods of treatment to overcome chemotherapy-resistant tumors. The presence of 
hypermethylated RASSF1A, APC, CDKN2A, GSTP1, and PTGS2 in the cell-free serum DNA 
of TGCT patients raises the important question of how early in the tumorigenic process 
these markers could be detected at interpretable levels. Optimizing this strategy of 
identifying potential TGCTs before they develop to the extent of requiring aggressive 
chemotherapy and radiation treatment will be an important endeavor during the next 
decade. Because some metastatic TGCTs are refractory to cisplatin-based chemotherapy, 
searching for an alternative treatment regimen for these tumors is equally important. The 
potential use of 5-azacytidine, or similar DNMT inhibitors, in overcoming cisplatin 
resistance holds promise for such cases. Further investigation of epigenetic modifications in 
TGCTs at the bench and in the clinic will address these goals. 
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